First-line carboplatin-cyclophosphamide (CC) versus paclitaxel (P) with or without atezolizumab (atezo) for metastatic triple negative breast cancer (mTNBC): Results from a multicenter, randomized phase IIb trial: The Triple-B study (BOOG 2013-01)

被引：0
|
作者：
Kok, M. [1 ]
Voorthuis, R. A. B. [2 ]
De Boo, L. [2 ]
van Rossum, A. G. J. [2 ]
Mandjes, I. [3 ]
Balduzzi, S. [4 ]
Chelushkin, M. [5 ]
Rosenberg, E. H. [6 ]
Horlings, H. M. [7 ]
Loo, C. E. [8 ]
Heijns, J. B. [9 ]
Agterhof, M. [10 ]
De Valk, B. [11 ]
Riel, A-M. V. [12 ]
Van der Velden, A. [13 ]
Dercksen, M. [14 ]
Imholz, A. [15 ]
van Leeuwen-Stok, A. E. [16 ]
Oosterkamp, H. M. [17 ]
Linn, S. [18 ]
机构：
[1] Netherlands Canc Inst, Med Oncol Dept, Amsterdam, Netherlands
[2] Antoni van Leeuwenhoek Hosp, NKI AVL Netherlands Canc Inst, Mol Pathol Dept, Amsterdam, Netherlands
[3] Netherlands Canc Inst, Dept Biometr, Amsterdam, Netherlands
[4] NKI Netherlands Canc Inst, Dept Biometr, Amsterdam, Netherlands
[5] Antoni van Leeuwenhoek Hosp, NKI AVL Netherlands Canc Inst, Tumor Biol & Immunol, Amsterdam, Netherlands
[6] Antoni van Leeuwenhoek Hosp, NKI AVL Netherlands Canc Inst, Dept Pathol, Amsterdam, Netherlands
[7] Antoni van Leeuwenhoek Hosp, NKI AVL Netherlands Canc Inst, Pathol, Amsterdam, Netherlands
[8] Antoni van Leeuwenhoek Hosp, NKI AVL Netherlands Canc Inst, Radiol, Amsterdam, Netherlands
[9] Amphia Ziekenhuis Locat Molengracht, Oncol Dept, Breda, Netherlands
[10] St Antonius Hosp, Interne Geneeskunde, Nieuwegein, Netherlands
[11] Spaarne Hosp Hoofddorp, Med Oncol Dept, Hoofddorp, Netherlands
[12] ETZ Elisabeth Hosp, Med Oncol Dept, Tilburg, Netherlands
[13] Martini Hosp, Internal Med Dept, Groningen, Netherlands
[14] Maxima Med Ctr Veldhoven, Med Oncol, Veldhoven, Netherlands
[15] Deventer Ziekenhuis, Med Oncol, Deventer, Netherlands
[16] BOOG Study Ctr, Dutch Breast Canc Res Grp, Utrecht, Netherlands
[17] HMC Haaglanden Med Ctr Westeinde, Med Oncol, The Hague, Netherlands
[18] Antoni van Leeuwenhoek Hosp, NKI AVL Netherlands Canc Inst, Med Oncol Dept, Amsterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.2258
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA20
引用
收藏
页码：1213 / 1213
页数：1
相关论文
共 50 条
  • [41] Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
    Hans-Joachim Lück
    Andreas Du Bois
    Sibylle Loibl
    Iris Schrader
    Jens Huober
    Volker Heilmann
    Matthias Beckmann
    Ann Stähler
    Christian Jackisch
    Michael Hubalek
    Barbara Richter
    Elmar Stickeler
    Holger Eidtmann
    Christoph Thomssen
    Michael Untch
    Kerstin Wollschläger
    Tibor Schuster
    Gunter von Minckwitz
    Breast Cancer Research and Treatment, 2013, 139 : 779 - 787
  • [42] Safety and efficacy of first-line epirubicin-docetaxel versus epirubicin-cyclophosphamide: updated results of a multicenter randomized phase III trial in metastatic breast cancer.
    Blohmer, JU
    Houschild, M
    Hilfrich, J
    Kleine-Tebbe, A
    Lichtenegger, W
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S199 - S199
  • [43] Randomized phase II trial comparing docetaxel with or without low-dose metronomic oral cyclophosphamide in first-line treatment of non-triple-negative advanced breast cancer
    Wang, Leiping
    Zhang, Jian
    Wang, Zhong Hua
    Wang, Biyun
    Cao, Jun
    Lv, Fangfang
    Zhang, Sheng
    Shao Zhimin
    Hu, Xi-Chun
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] Genomic profiling and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: An exploratory analysis from the phase 3 IMpassion130 trial
    Emens, Leisha
    Molinero, Luciana
    Adams, Sylvia
    Rugo, Hope S.
    Schneeweiss, Andreas
    Dieras, Veronique
    Iwata, Hiroji
    Barrios, Carlos
    Winer, Eric P.
    Chang, Ching-Wei
    Chui, Stephen Y.
    Schmid, Peter
    Loi, Sherene
    CANCER RESEARCH, 2021, 81 (04)
  • [45] Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) plus paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)
    Dent, R.
    Oliveira, M.
    Isakoff, S. J.
    Im, S-A.
    Espie, M.
    Blau, S.
    Tan, A. R.
    Saura, C.
    Wongchenko, M.
    Xu, N.
    Bradley, D.
    Reilly, S-J.
    Mani, A.
    Kim, S-B.
    ANNALS OF ONCOLOGY, 2020, 31 : S64 - S65
  • [46] Docetaxel versus epirubicin/cyclophosphamide (EC) as first-line therapy in metastatic breast cancer (MBC): Results from the randomized phase II TIPP study.
    Wasemann, C
    Ertan, A
    Strunck, C
    Schmidt, W
    Diedrich, K
    Friedrich, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 82S - 82S
  • [47] Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) plus paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC)
    Dent, Rebecca
    Im, Seock-Ah
    Espie, Marc
    Blau, Sibel
    Tan, Antoinette R.
    Isakoff, Steven J.
    Oliveira, Mafalda
    Saura, Cristina
    Wongchenko, Matthew
    Kapp, Amy V.
    Chan, Wai Y.
    Singel, Stina M.
    Maslyar, Daniel J.
    Baselga, Jose
    Kim, Sung-Bae
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer
    Dent, Rebecca
    Oliveira, Mafalda
    Isakoff, Steven J.
    Im, Seock-Ah
    Espie, Marc
    Blau, Sibel
    Tan, Antoinette R.
    Saura, Cristina
    Wongchenko, Matthew J.
    Xu, Na
    Bradley, Denise
    Reilly, Sarah-Jayne
    Mani, Aruna
    Kim, Sung-Bae
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (02) : 377 - 386
  • [49] Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer
    Rebecca Dent
    Mafalda Oliveira
    Steven J. Isakoff
    Seock-Ah Im
    Marc Espié
    Sibel Blau
    Antoinette R. Tan
    Cristina Saura
    Matthew J. Wongchenko
    Na Xu
    Denise Bradley
    Sarah-Jayne Reilly
    Aruna Mani
    Sung-Bae Kim
    Breast Cancer Research and Treatment, 2021, 189 : 377 - 386
  • [50] Randomized, open-label, phase III, multicenter trial comparing AT (doxorubicin, paclitaxel) versus FAC (5-fluorouracil, doxorubicin, cyclophosphamide) as first-line treatment for patients with metastatic breast cancer
    Tjulandin, SA
    SEMINARS IN ONCOLOGY, 1999, 26 (06) : 10 - 10
12345